Our Indications

Indications

Anti-microbial resistance (AMR), a “silent pandemic”, is one of the top global health threats, estimated to be directly responsible for 1.45 million deaths world-wide and to have contributed to 5.35 million additional deaths in 2022 only.
AMR arises when pathogens undergo mutations or evolutionary changes that diminish the efficacy of antimicrobial agents. Misuse and overuse of antibiotics exacerbate this resistance, rendering infections increasingly challenging to treat. This escalates the risk of disease transmission, contributes to the development of severe diseases and increases mortality rates.

Revium’s liposomal nano-mupirocin is a formulation of the approved, highly effective anti-bacterial drug mupirocin which is currently limited to topical use. The novel proprietary formulation of nano-mupirocin will be administered systemically, providing long circulation time and enhanced delivery of mupirocin to inflammation sites. In several preclinical studies carried out by NIH STI group, nano-mupirocin has demonstrated low minimum inhibitory concentration (MIC) levels as well as excellent efficacy in preclinical models against multiple resistant bacterial strains, including MRSA and VRE.

Checkpoint inhibitors (ICIs) exhibit substantial promise in combating cancer by restoring or activating the immune system. However, multiple mechanisms contribute to immunotherapy resistance of malignant cells, with the hard-to-penetrate tumor microenvironment (TME) being a major factor that limits the efficacy of ICIs and other immune-modulating therapeutics. Preclinical and clinical data suggests that angiotensin receptor blockers (ARBs), commonly used to treat hypertension, can potentially augment the beneficial effects of ICIs by modifying the TME. However, the systemic administration of ARBs is complicated by their blood pressure-lowering effect.

Revium Rx develops nanoparticle-encapsulated candesartan (approved ARB) as a tumor-targeted and safe adjuvant to ICIs treatment. The novel adjuvant developed by Revium aims to overcome the limitation of systemic ARB administration and significantly improve treatment success rates by enabling enhanced permeability and retention (EPR effect) without affecting systemic blood pressure. Preclinical studies carried out at the Hebrew University of Jerusalem have shown that ARB targeting can effectively modulate the immune response within tumors, increasing the effectiveness of current therapies.

The critical need for vaccine development is especially pronounced in the context of emerging and re-emerging infectious diseases. These diseases present substantial, global health threats, yet effective vaccines remain limited or unavailable. Slow vaccine development can be attributed to several factors, including market disincentives, biological complexities, and regulatory challenges.

Comprised of a unique assembly of novel lipids with biological components, our lipid-based Protein-Loaded Technology (LPLT) microparticles have demonstrated promising efficacy in preclinical models of infectious diseases. The unique lipids utilized in the formulation modify the immune response in animal models specifically and effectively, potentially holding significant clinical opportunities for COVID-19, West Nile, and Zika viruses.